Results 11 to 20 of about 2,329 (147)

Ozanimod: A Practical Review for Nurses and Advanced Practice Providers [PDF]

Nursing (Auckland, N Z )
Michele Rubin,1 Christen Kutz2 1Department of Colorectal Surgery, University of Chicago IBD Center, Joliet, IL, USA; 2Colorado Springs Neurological Associates, Colorado Springs, CO, USACorrespondence: Michele Rubin, Associate Director of IBD Center ...
Rubin M, Kutz C
exaly   +5 more sources

Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus. [PDF]

PLoS ONE, 2018
Ozanimod (RPC1063) is a specific and potent small molecule modulator of the sphingosine 1-phosphate receptor 1 (S1PR1) and receptor 5 (S1PR5), which has shown therapeutic benefit in clinical trials of relapsing multiple sclerosis and ulcerative colitis ...
Kristen R Taylor Meadows, Marcos W Steinberg, Bryan Clemons, Matthew E Stokes, Gregory J Opiteck, Robert Peach, Fiona L Scott   +6 more
doaj   +2 more sources

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States

Neurology and Therapy, 2023
Introduction This study assessed the cost-effectiveness of ozanimod compared with commonly used disease-modifying therapies (DMTs) for relapsing–remitting multiple sclerosis (RRMS). Methods Annualized relapse rate (ARR) and safety data were obtained from
Daniel Kantor, Timothy Pham, Oscar Patterson-Lomba, Elyse Swallow, Akanksha Dua, Komal Gupte-Singh   +5 more
doaj   +2 more sources

SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis [PDF]

Annals of Clinical and Translational Neurology, 2023
Objective To investigate the serologic response, predictors of response, and clinical outcomes associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination and infection in ozanimod‐treated participants with relapsing multiple
Bruce A. C. Cree, Rachel Maddux, Amit Bar‐Or, Hans‐Peter Hartung, Amandeep Kaur, Elizabeth Brown, Yicong Li, Yanhua Hu, James K. Sheffield, Diego Silva, Sarah Harris   +10 more
doaj   +2 more sources

Ozanimod-mediated remission in experimental autoimmune encephalomyelitis is associated with enhanced activity of CNS CD27low/- NK cell subset

Frontiers in Immunology
BackgroundOzanimod (RPC1063) is an immunomodulator that has been recently approved by the FDA (2020) for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Doua Kamyan, Maya Hassane, Alanood Alnaqbi, Abdul-Kader Souid, Zakeya Al Rasbi, Abeer Al Tahrawi, Mariam Al Shamsi   +6 more
doaj   +2 more sources

Comparative effectiveness and safety of ozanimod other oral DMTs in relapsing-remitting multiple sclerosis: a synthesis of matching-adjusted indirect comparisons

Therapeutic Advances in Neurological Disorders
Background: Several oral disease-modifying therapies (DMTs) have been approved by the Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Damemarie Paul, Elyse Swallow, Oscar Patterson-Lomba, Tychell Branchcomb, Laetitia N’Dri, Andres Gomez-Lievano, Jingyi Liu, Akanksha Dua, Marisa McGinley   +8 more
doaj   +2 more sources

An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis [PDF]

Drug Design, Development and Therapy, 2021
Marzia Fronza,1 Lorena Lorefice,2 Jessica Frau,2 Eleonora Cocco1,2 1Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy; 2Multiple Sclerosis Center, Binaghi Hospital, ATS Sardegna, ASSL Cagliari, Cagliari ...
Fronza M, Lorefice L, Frau J, Cocco E
doaj   +2 more sources

Comparative Efficacy of Mesalazine and Ozanimod following Induction Treatment in Mesalazine-Exposed Advanced Therapy-Naïve Adult Ulcerative Colitis Patients

Inflammatory Intestinal Diseases
Introduction: Both mesalazine and ozanimod are oral treatment options for patients with moderately active ulcerative colitis (UC). Methods: Comparative analysis comparing efficacy endpoints of an 8-week non-inferiority induction study (TP0503)
Geert D'Haens, Ekaterina Safroneeva, Laurent Peyrin-Biroulet, Silvio Danese, Vipul Jairath, Helen Thorne, Raphaël Laoun   +6 more
doaj   +2 more sources

Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitis.

Journal of Comparative Effectiveness Research
Aim: Etrasimod and ozanimod are selective sphingosine 1-phosphate receptor modulators targeting the S1P1,4,5, and S1P1,5 receptors, respectively, for the treatment of patients with moderately to severely active ulcerative colitis (UC).
Joseph C Cappelleri, Ravi Potluri, Tim Raine   +2 more
exaly   +2 more sources

Safety of ozanimod and etrasimod in ulcerative colitis: A disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System database. [PDF]

Medicine (Baltimore)
Ozanimod and etrasimod are sphingosine-1-phosphate receptor modulators approved for ulcerative colitis treatment.
Chen L, Wan D, Xing B, Ji X, Zhou W, Liu Y, Lu Y.   +6 more
europepmc   +2 more sources